GALWAY, Ireland, Oct. 15,
2024 /PRNewswire/ -- AuriGen Medical, a medical
device company specializing in left atrial appendage occlusion
(LAAO) technology, today announced the successful treatment of
their first patient in its first-in-human clinical study. The
procedure, performed by Dr Matt
O'Connor, Cardiologist and Electrophysiologist at Auckland
City Hospital New Zealand, marks a significant milestone in the
clinical validation of AuriGen's novel "Zenith" LAAO device.
Atrial fibrillation ("AF") affects over 60 million people
worldwide and significantly increases stroke risk, with over 90% of
stroke-causing clots originating in the left atrial appendage
("LAA"). This makes LAA closure vital for patients who cannot
tolerate long-term anticoagulation therapy. The Zenith device
simplifies LAA closure, crucial for reducing stroke risk in AF
patients.
Zenith is implanted through a quick, minimally invasive
procedure via a small groin incision. The delivery system guides
the implant to the heart sealing the LAA and offers fully
controllable deployment which adapts to each patient's unique
anatomy for a precise fit. Zenith is designed for non-traumatic
repositioning, allowing physicians to perform leak-checks and
real-time adjustments. Zenith's unique self-closing covering
encourages heart tissue-growth, designed to support healing and
long-term LAA closure.
"I am very encouraged by how the Zenith device performed in this
important first case. The patient recovered exceptionally well and
has been discharged home" said Dr Matt
O'Connor. "From a physician's perspective, Zenith's
independent anchors provide a distinct advantage by allowing easy
repositioning and placement optimization of the implant without
risking injury to the heart. This in combination with the
intra-procedural leak analysis, represents a significant advance in
the left atrial appendage occlusion technology available to our AF
patients who are at significant stroke risk."
"This first-in-human procedure of the Zenith device is a huge
milestone for AuriGen Medical," said the company's Chairman
Pierre Chauvineau. "It marks a
critical step forward in LAAO technology. As we advance our
clinical trials, we are committed to improving outcomes for our
LAAO patients and exploring new Zenith applications that can
benefit a wider range of cardiac patients."
About AuriGen Medical
AuriGen Medical is a clinical-stage medical device company focused
on developing novel minimally invasive technologies for patients
with chronic heart disease. AuriGen, funded by Western Development
Commission and Enterprise Ireland DTI fund, has been awarded
three EU Horizon Europe awards, highlighting it's innovative,
disruptive technology. www.AuriGenMedical.com
Photo -
https://mma.prnewswire.com/media/2528695/AuriGen_Medical.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/aurigen-medical-pioneers-next-generation-atrial-fibrillation-technology-with-first-in-human-success-302275234.html